Comparison Overview

AUROBINDO PHARMA LTD

VS

PT Kalbe Farma, Tbk

AUROBINDO PHARMA LTD

Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District,, Hyderabad, Telangana, IN, 500032
Last Update: 2025-12-17
View Profile
Between 750 and 799
https://www.aurobindo.com/

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 14,616
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

PT Kalbe Farma, Tbk

KALBE Building, Jl. Letjen Suprapto Kav 4, Jakarta, DKI Jakarta, ID, 10510
Last Update: 2025-12-17
Between 750 and 799
http://www.kalbe.co.id/

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 12,334
Subsidiaries: 1
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/aurobindopharma.jpeg
AUROBINDO PHARMA LTD
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/pt-kalbe-farma.jpeg
PT Kalbe Farma, Tbk
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
AUROBINDO PHARMA LTD
100%
Compliance Rate
0/4 Standards Verified
PT Kalbe Farma, Tbk
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for AUROBINDO PHARMA LTD in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for PT Kalbe Farma, Tbk in 2025.

Incident History — AUROBINDO PHARMA LTD (X = Date, Y = Severity)

AUROBINDO PHARMA LTD cyber incidents detection timeline including parent company and subsidiaries

Incident History — PT Kalbe Farma, Tbk (X = Date, Y = Severity)

PT Kalbe Farma, Tbk cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/aurobindopharma.jpeg
AUROBINDO PHARMA LTD
Incidents

No Incident

https://images.rankiteo.com/companyimages/pt-kalbe-farma.jpeg
PT Kalbe Farma, Tbk
Incidents

No Incident

FAQ

PT Kalbe Farma, Tbk company demonstrates a stronger AI Cybersecurity Score compared to AUROBINDO PHARMA LTD company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, PT Kalbe Farma, Tbk company has disclosed a higher number of cyber incidents compared to AUROBINDO PHARMA LTD company.

In the current year, PT Kalbe Farma, Tbk company and AUROBINDO PHARMA LTD company have not reported any cyber incidents.

Neither PT Kalbe Farma, Tbk company nor AUROBINDO PHARMA LTD company has reported experiencing a ransomware attack publicly.

Neither PT Kalbe Farma, Tbk company nor AUROBINDO PHARMA LTD company has reported experiencing a data breach publicly.

Neither PT Kalbe Farma, Tbk company nor AUROBINDO PHARMA LTD company has reported experiencing targeted cyberattacks publicly.

Neither AUROBINDO PHARMA LTD company nor PT Kalbe Farma, Tbk company has reported experiencing or disclosing vulnerabilities publicly.

Neither AUROBINDO PHARMA LTD nor PT Kalbe Farma, Tbk holds any compliance certifications.

Neither company holds any compliance certifications.

PT Kalbe Farma, Tbk company has more subsidiaries worldwide compared to AUROBINDO PHARMA LTD company.

AUROBINDO PHARMA LTD company employs more people globally than PT Kalbe Farma, Tbk company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither AUROBINDO PHARMA LTD nor PT Kalbe Farma, Tbk holds SOC 2 Type 1 certification.

Neither AUROBINDO PHARMA LTD nor PT Kalbe Farma, Tbk holds SOC 2 Type 2 certification.

Neither AUROBINDO PHARMA LTD nor PT Kalbe Farma, Tbk holds ISO 27001 certification.

Neither AUROBINDO PHARMA LTD nor PT Kalbe Farma, Tbk holds PCI DSS certification.

Neither AUROBINDO PHARMA LTD nor PT Kalbe Farma, Tbk holds HIPAA certification.

Neither AUROBINDO PHARMA LTD nor PT Kalbe Farma, Tbk holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

A vulnerability has been found in SeaCMS up to 13.3. The affected element is an unknown function of the file js/player/dmplayer/dmku/class/mysqli.class.php. Such manipulation of the argument page/limit leads to sql injection. The attack can be executed remotely. The exploit has been disclosed to the public and may be used.

Published
Date
2025-12-21
Updated
Date
2025-12-21
Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') vulnerability in HappyDevs TempTool allows Stored XSS.This issue affects TempTool: from n/a through 1.3.1.

Published
Date
2025-12-21
Updated
Date
2025-12-21
Risk Information
cvss3
Base: 6.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:L
References
Description

Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') vulnerability in Tormorten WP Microdata allows Stored XSS.This issue affects WP Microdata: from n/a through 1.0.

Published
Date
2025-12-21
Updated
Date
2025-12-21
Risk Information
cvss3
Base: 6.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:L
References
Description

Exposure of Sensitive System Information to an Unauthorized Control Sphere vulnerability in HappyDevs TempTool allows Retrieve Embedded Sensitive Data.This issue affects TempTool: from n/a through 1.3.1.

Published
Date
2025-12-21
Updated
Date
2025-12-21
Risk Information
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N
References
Description

A vulnerability has been found in Tenda FH1201 1.2.0.14(408). Affected is the function sprintf of the file /goform/SetIpBind. Such manipulation of the argument page leads to stack-based buffer overflow. The attack may be performed from remote. The exploit has been disclosed to the public and may be used.

Published
Date
2025-12-21
Updated
Date
2025-12-21
Risk Information
cvss2
Base: 9.0
Severity: LOW
AV:N/AC:L/Au:S/C:C/I:C/A:C
cvss3
Base: 8.8
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
cvss4
Base: 7.4
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References